enGene (NASDAQ:ENGN) Issues Quarterly Earnings Results, Beats Expectations By $0.06 EPS

enGene (NASDAQ:ENGN) released its earnings results on Thursday. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.06, Zacks reports.

enGene Stock Performance

Shares of ENGN stock traded up $0.03 during mid-day trading on Thursday, hitting $5.96. 57,410 shares of the stock were exchanged, compared to its average volume of 118,135. enGene has a 12-month low of $4.42 and a 12-month high of $18.40. The company has a debt-to-equity ratio of 0.09, a quick ratio of 19.52 and a current ratio of 19.52. The stock has a market capitalization of $263.53 million, a price-to-earnings ratio of -3.66 and a beta of -0.78. The stock’s fifty day simple moving average is $8.18 and its two-hundred day simple moving average is $7.82.

Analyst Ratings Changes

ENGN has been the subject of a number of recent research reports. JMP Securities reiterated a “market outperform” rating and issued a $18.00 target price on shares of enGene in a report on Friday, December 6th. Morgan Stanley reissued an “overweight” rating and set a $40.00 price objective on shares of enGene in a research report on Wednesday, September 11th. Oppenheimer reaffirmed an “outperform” rating and issued a $30.00 target price on shares of enGene in a report on Tuesday, September 24th. Citizens Jmp upgraded shares of enGene to a “strong-buy” rating in a report on Monday, November 18th. Finally, Raymond James initiated coverage on shares of enGene in a research report on Wednesday, November 27th. They set an “outperform” rating and a $23.00 price objective for the company. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, enGene currently has an average rating of “Buy” and an average price target of $30.38.

Insider Buying and Selling

In related news, CEO Ronald Harold Wilfred Cooper purchased 10,000 shares of the company’s stock in a transaction that occurred on Friday, September 27th. The shares were purchased at an average price of $5.70 per share, for a total transaction of $57,000.00. Following the transaction, the chief executive officer now directly owns 10,000 shares of the company’s stock, valued at approximately $57,000. The trade was a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Growth Opportunities F. Forbion purchased 11,844 shares of the company’s stock in a transaction dated Monday, October 7th. The shares were purchased at an average price of $6.55 per share, for a total transaction of $77,578.20. Following the completion of the purchase, the insider now owns 2,469,833 shares of the company’s stock, valued at approximately $16,177,406.15. This trade represents a 0.48 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought 420,965 shares of company stock worth $2,651,103 in the last quarter. 13.70% of the stock is owned by insiders.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.